Measuring success of adjuvant treatment for patients with melanoma
Mené sur 1 019 patients atteints d'un mélanome de stade III ayant été réséqué, cet essai multicentrique de phase III évalue l'intérêt, du point de vue de la qualité de vie, du pembrolizumab en traitement adjuvant
Most people diagnosed with melanoma have their disease successfully treated by surgery alone, but about 20% are at high risk of recurrence after surgery, with potentially life-threatening consequences. Adjuvant immunotherapy has been routinely available for this population since 2017. The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 study, which evaluated pembrolizumab, was a practice-changing trial 1 underpinning a body of data supporting the role of adjuvant immune checkpoint inhibitor therapy for melanoma.
The Lancet Oncology 2023